



## Clinical trial results:

### A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India

#### Summary

EudraCT number	2008-003687-20
Trial protocol	Outside EU/EEA
Global end of trial date	13 October 2009

#### Results information

Result version number	v1 (current)
This version publication date	29 June 2016
First version publication date	05 August 2015

#### Trial information

##### Trial identification

Sponsor protocol code	6096A1-011
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00452790
WHO universal trial number (UTN)	-
Other trial identifiers	Alias: B1851002

Notes:

#### Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 May 2010
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	13 October 2009
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

- To assess the pneumococcal immune responses induced by 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) relative to the pneumococcal immune responses induced by 7-Valent Pneumococcal Conjugate Vaccine (7vPnC) when measured 1 month after the infant series.
- To assess the immune responses induced by diphtheria, tetanus, whole cell pertussis; Haemophilus influenzae (H influenzae) type b (Hib); and hepatitis B vaccine (DTP-Hib-HBV) given with 13vPnC relative to the immune responses induced by DTP-Hib-HBV given with 7vPnC when measured 1 month after the infant series. The following antigens in DTP-Hib-HBV will be assessed: pertussis antigens (pertussis toxoid [PT], filamentous haemagglutinin [FHA], and pertactin [PRN]).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 July 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	India: 709
Worldwide total number of subjects	709
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	709
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

708 subjects were enrolled and 709 were randomized into the study. One infant in the 13vPnC group was randomly assigned twice because of technical difficulties with the first random assignment. Though this infant participated in the study only once, both random assignments were included in the 354 subjects in the 13vPnC group.

### Period 1

Period 1 title	Infant Series
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	13vPnC: Infant series

Arm description:

Subjects received 1 single dose of 13vPnC, at 6, 10 and 14 weeks of age co-administered with a commercially available combination vaccine containing diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).

Arm type	Experimental
Investigational medicinal product name	13vPnC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 0.5 milliliter (mL) dose of 13vPnC at 6, 10 and 14 weeks of age.

Investigational medicinal product name	DTP-Hib-HBV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received DTP-Hib-HBV dose at 6, 10 and 14 weeks of age.

Investigational medicinal product name	OPV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral liquid
Routes of administration	Oral use

Dosage and administration details:

Subjects received OPV dose at 6, 10 and 14 weeks of age.

<b>Arm title</b>	7vPnC: Infant Series
------------------	----------------------

Arm description:

Subjects received 1 single dose of 7vPnC at 6, 10 and 14 weeks of age co-administered with a commercially available combination vaccine DTP-Hib-HBV and a commercially available OPV.

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	7vPnC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Subjects received 0.5 mL dose of 7vPnC at 6, 10 and 14 weeks of age.	
Investigational medicinal product name	DTP-Hib-HBV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Subjects received DTP-Hib-HBV dose at 6, 10 and 14 weeks of age.	
Investigational medicinal product name	OPV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral liquid
Routes of administration	Oral use
Dosage and administration details:	
Subjects received OPV dose at 6, 10 and 14 weeks of age.	

<b>Number of subjects in period 1</b>	13vPnC: Infant series	7vPnC: Infant Series
Started	354	355
Vaccinated Dose 1	353	353
Vaccinated Dose 2	300	300
Vaccinated Dose 3	221	218
Completed	219	214
Not completed	135	141
Clinical hold - consent withdrawn	118	123
Failed to return	4	1
Adverse Event	1	2
Parent/legal guardian request	8	6
'Protocol Violation '	1	3
Other reasons	1	2
Lost to follow-up	2	2
'Death '	-	1
Investigator request	-	1

**Period 2**

Period 2 title	After Infant Series
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

**Arms**

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	13vPnC: After Infant series
------------------	-----------------------------

## Arm description:

Subjects who received 1 single dose of 13vPnC at 6, 10 and 14 weeks of age, co-administered with a commercially available combination vaccine containing DTP-Hib-HBV and a commercially available OPV in the infant series.

Arm type	No intervention
----------	-----------------

No investigational medicinal product assigned in this arm

<b>Arm title</b>	7vPnC: After Infant series
------------------	----------------------------

## Arm description:

Subjects who received 1 single dose of 7vPnC at 6, 10 and 14 weeks of age co-administered with a commercially available combination vaccine containing DTP-Hib-HBV and a commercially available OPV in the infant series.

Arm type	No intervention
----------	-----------------

No investigational medicinal product assigned in this arm

<b>Number of subjects in period 2</b>	13vPnC: After Infant series	7vPnC: After Infant series
Started	219	214
Completed	198	200
Not completed	21	14
Adverse Event	4	1
Failed to return	1	-
Parent/legal guardian request	1	3
Other reasons	1	-
Lost to follow-up	4	-
Investigator request	10	10

**Period 3**

Period 3 title	Toddler Dose
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

## Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	13vPnC: Toddler Dose
------------------	----------------------

Arm description:

Subjects received 1 single dose of 13vPnC administered at 12 months of age.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	13vPnC
--	--------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Suspension for injection
----------------------	--------------------------

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

Subjects received 0.5 mL dose of 13vPnC at 12 months of age.

<b>Arm title</b>	7vPnC: Toddler Dose
------------------	---------------------

Arm description:

Subjects received 1 single dose of 7vPnC administered at 12 months of age.

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	7vPnC
--	-------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Suspension for injection
----------------------	--------------------------

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

Subjects received 0.5 mL dose of 7vPnC at 12 months of age.

Number of subjects in period 3	13vPnC: Toddler Dose	7vPnC: Toddler Dose
Started	198	200
Completed	198	198
Not completed	0	2
'Parent/legal guardian request '	-	1
Failed to return	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	13vPnC: Infant series
Reporting group description:	
Subjects received 1 single dose of 13vPnC, at 6, 10 and 14 weeks of age co-administered with a commercially available combination vaccine containing diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).	
Reporting group title	7vPnC: Infant Series
Reporting group description:	
Subjects received 1 single dose of 7vPnC at 6, 10 and 14 weeks of age co-administered with a commercially available combination vaccine DTP-Hib-HBV and a commercially available OPV.	

Reporting group values	13vPnC: Infant series	7vPnC: Infant Series	Total
Number of subjects	354	355	709
Age categorical Units: Subjects			
Age continuous Units: months arithmetic mean standard deviation	1.6 ± 0.3	1.6 ± 0.2	-
Gender categorical Units: Subjects			
Female	169	169	338
Male	184	186	370
Unknown	1	0	1
Age continuous Units: weeks arithmetic mean standard deviation	7.1 ± 1.1	7.2 ± 1.1	-



## End points

### End points reporting groups

Reporting group title	13vPnC: Infant series
Reporting group description: Subjects received 1 single dose of 13vPnC, at 6, 10 and 14 weeks of age co-administered with a commercially available combination vaccine containing diphtheria, tetanus, whole cell pertussis; H influenzae type b and hepatitis B vaccine (DTP-Hib-HBV); and a commercially available oral polio vaccine (OPV).	
Reporting group title	7vPnC: Infant Series
Reporting group description: Subjects received 1 single dose of 7vPnC at 6, 10 and 14 weeks of age co-administered with a commercially available combination vaccine DTP-Hib-HBV and a commercially available OPV.	
Reporting group title	13vPnC: After Infant series
Reporting group description: Subjects who received 1 single dose of 13vPnC at 6, 10 and 14 weeks of age, co-administered with a commercially available combination vaccine containing DTP-Hib-HBV and a commercially available OPV in the infant series.	
Reporting group title	7vPnC: After Infant series
Reporting group description: Subjects who received 1 single dose of 7vPnC at 6, 10 and 14 weeks of age co-administered with a commercially available combination vaccine containing DTP-Hib-HBV and a commercially available OPV in the infant series.	
Reporting group title	13vPnC: Toddler Dose
Reporting group description: Subjects received 1 single dose of 13vPnC administered at 12 months of age.	
Reporting group title	7vPnC: Toddler Dose
Reporting group description: Subjects received 1 single dose of 7vPnC administered at 12 months of age.	

### **Primary: Percentage of Subjects Achieving a Predefined Antibody Level of Greater Than or Equal to ( $\geq$ ) 0.35 Micrograms per Milliliter (mcg/mL), 1 Month After the Infant Series.**

End point title	Percentage of Subjects Achieving a Predefined Antibody Level of Greater Than or Equal to ( $\geq$ ) 0.35 Micrograms per Milliliter (mcg/mL), 1 Month After the Infant Series. <sup>[1]</sup>
End point description: Percentage of subjects achieving a predefined antibody level of $\geq 0.35$ mcg/mL along with the corresponding O'Brien-Fleming-adjusted, exact, 2-sided 95 percent (%) confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19 A) are presented. Evaluable immunogenicity population: had treatments as randomized at all 3 doses, blood drawn within specified timeframes, had at least 1 valid and determinate assay result for the proposed analysis, and no major protocol violations. n=number of subjects with determinate IgG antibody concentration for the specified serotype.	
End point type	Primary
End point timeframe: 1 month after the infant series (18 weeks of age)	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported for this endpoint.	

End point values	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	206	196		
Units: Percentage of subjects				
number (confidence interval 95.2%)				
Common serotypes - serotype 4 (n= 203, 192)	97 (93.6 to 98.9)	97.9 (94.7 to 99.4)		
Common serotypes - serotype 6B (n= 196,194)	84.7 (78.8 to 89.5)	87.1 (81.5 to 91.5)		
Common serotypes - serotype 9V (n= 204,195)	92.6 (88.1 to 95.8)	94.4 (90.1 to 97.2)		
Common serotypes - serotype 14 (n= 185,186)	91.4 (86.3 to 95)	93.5 (89 to 96.6)		
Common serotypes - serotype 18C (n= 204,188)	95.1 (91.1 to 97.6)	93.1 (88.4 to 96.3)		
Common serotypes - serotype 19F (n= 200,188)	95 (91 to 97.6)	94.7 (90.4 to 97.4)		
Common serotypes - serotype 23F (n= 202,186)	90.1 (85.1 to 93.9)	89.2 (83.8 to 93.3)		
Additional serotypes - serotype 1 (n= 206,195)	96.6 (93.1 to 98.6)	0.5 (0 to 2.8)		
Additional serotypes - serotype 3 (n= 201,187)	87.6 (82.1 to 91.8)	2.1 (0.6 to 5.4)		
Additional serotypes - serotype 5 (n= 201,185)	85.1 (79.3 to 89.7)	24.3 (18.3 to 31.2)		
Additional serotypes - serotype 6A (n= 200,191)	90 (84.9 to 93.8)	36.1 (29.3 to 43.4)		
Additional serotypes - serotype 7F (n= 203,192)	98 (95 to 99.5)	2.6 (0.8 to 6)		
Additional serotypes - serotype 19 A (n= 204,190)	99.5 (97.3 to 100)	84.7 (78.8 to 89.6)		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects Achieving a Predefined Antibody Level for Concomitant Vaccine Pertussis Antigens (Pertussis Toxoid [PT], Filamentous Hemagglutinin [FHA], Pertactin [PRN]), 1 Month After the Infant Series.

End point title	Percentage of Subjects Achieving a Predefined Antibody Level for Concomitant Vaccine Pertussis Antigens (Pertussis Toxoid [PT], Filamentous Hemagglutinin [FHA], Pertactin [PRN]), 1 Month After the Infant Series. <sup>[2]</sup>
-----------------	--

End point description:

Percentage of subjects achieving a predefined antibody level (measured in enzyme-linked immunosorbent assay [ELISA] units per mL [EU/mL]) along with the corresponding O'Brien-Fleming-adjusted, exact, 2-sided 95% CI for concomitant antigens pertussis (PT, FHA and PRN) are presented. Evaluable immunogenicity population: had treatments as randomized at all 3 doses, blood drawn within specified timeframes, had at least 1 valid and determinate assay result for the proposed analysis, and no major protocol violations.

End point type	Primary
----------------	---------

End point timeframe:

1 month after the infant series (18 weeks of age)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	206	196		
Units: Percentage of subjects				
number (confidence interval 95.2%)				
PT $\geq 0.975$ EU/mL	100 (98.2 to 100)	100 (98.1 to 100)		
FHA $\geq 3.91$ EU/mL	100 (98.2 to 100)	100 (98.1 to 100)		
PRN $\geq 6$ EU/mL	92.7 (88.2 to 95.9)	95.9 (92.1 to 98.2)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Mcg/mL, 1 Month After the Toddler Dose.

End point title	Percentage of Subjects Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Mcg/mL, 1 Month After the Toddler Dose.
-----------------	---

End point description:

Percentage of subjects achieving a predefined antibody level of  $\geq 0.35$  mcg/mL along with the corresponding exact, 2-sided 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19 A) are presented. Evaluable immunogenicity population: had treatments as randomized at all 4 doses, blood drawn within specified timeframes, had at least 1 valid and determinate assay result for the proposed analysis, and no major protocol violations. n=number of subjects with determinate IgG antibody concentration for the specified serotype.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after the toddler dose (13 months of age)

End point values	13vPnC: Toddler Dose	7vPnC: Toddler Dose		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	193	196		
Units: Percentage of subjects				
number (confidence interval 95%)				
Common serotypes - serotype 4 (n=193, 196)	100 (98.1 to 100)	100 (98.1 to 100)		
Common serotypes - serotype 6B (n=192,195)	100 (98.1 to 100)	99.5 (97.2 to 100)		
Common serotypes - serotype 9V (n=193,196)	99.5 (97.1 to 100)	99.5 (97.2 to 100)		

Common serotypes - serotype 14 (n= 193,196)	99.5 (97.1 to 100)	99.5 (97.2 to 100)		
Common serotypes - serotype 18C (n= 193,196)	99.5 (97.1 to 100)	99 (96.4 to 99.9)		
Common serotypes - serotype 19F (n= 193,196)	97.9 (94.8 to 99.4)	98 (94.9 to 99.4)		
Common serotypes - serotype 23F (n= 193,196)	98.4 (95.5 to 99.7)	99.5 (97.2 to 100)		
Additional serotypes - serotype 1 (n= 193,195)	98.4 (95.5 to 99.7)	3.1 (1.1 to 6.6)		
Additional serotypes - serotype 3 (n= 193,194)	90.2 (85.1 to 94)	12.9 (8.5 to 18.4)		
Additional serotypes - serotype 5 (n= 192,183)	100 (98.1 to 100)	74.3 (67.4 to 80.5)		
Additional serotypes - serotype 6A (n= 193,194)	100 (98.1 to 100)	92.8 (88.2 to 96)		
Additional serotypes - serotype 7F (n= 193,194)	99 (96.3 to 99)	9.8 (6 to 14.9)		
Additional serotypes - serotype 19 A (n= 193,194)	100 (98.1 to 100)	98.5 (95.5 to 99.7)		

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody, 1 Month After the 3-Dose Infant Series

End point title	Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody, 1 Month After the 3-Dose Infant Series
-----------------	---

End point description:

Antibody GMC as measured in mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding O'Brien-Fleming-adjusted, 2-sided 95% CIs were calculated. Evaluable immunogenicity population: had treatments as randomized at all 3 doses, blood drawn within specified timeframes, had at least 1 valid and determinate assay result for the proposed analysis, and no major protocol violations. n=number of subjects with determinate IgG antibody concentration for the specified serotype.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

1 month after the 3-dose infant series (18 weeks of age)

End point values	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	206	196		
Units: mcg/mL				
geometric mean (confidence interval 95.2%)				
Common serotypes - serotype 4 (n= 203,192)	2.19 (1.95 to 2.46)	2.58 (2.26 to 2.95)		
Common serotypes - serotype 6B (n= 196,194)	1.45 (1.2 to 1.75)	1.56 (1.28 to 1.89)		

Common serotypes - serotype 9V (n=204,195)	1.34 (1.19 to 1.5)	1.46 (1.28 to 1.65)		
Common serotypes - serotype 14 (n=185,186)	2.84 (2.35 to 3.43)	2.39 (1.98 to 2.9)		
Common serotypes - serotype 18C (n=204,188)	1.61 (1.42 to 1.82)	1.7 (1.47 to 1.96)		
Common serotypes - serotype 19F (n=200,188)	2.25 (1.97 to 2.56)	2.47 (2.11 to 2.89)		
Common serotypes - serotype 23F (n=202,186)	1.38 (1.18 to 1.6)	1.46 (1.25 to 1.7)		
Additional serotypes - serotype 1 (n=206,195)	1.95 (1.72 to 2.22)	0.03 (0.03 to 0.04)		
Additional serotypes - serotype 3 (n=201,187)	0.8 (0.72 to 0.9)	0.05 (0.05 to 0.06)		
Additional serotypes - serotype 5 (n=201,185)	0.93 (0.82 to 1.06)	0.2 (0.18 to 0.23)		
Additional serotypes - serotype 6A (n=200,191)	1.44 (1.25 to 1.66)	0.28 (0.25 to 0.31)		
Additional serotypes - serotype 7F (n=203,192)	2.27 (2.05 to 2.33)	0.06 (0.05 to 0.06)		
Additional serotypes - serotype 19A (n=204,190)	2.76 (2.46 to 3.1)	0.74 (0.66 to 0.82)		

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody, 1 Month After the Toddler Dose

End point title	Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody, 1 Month After the Toddler Dose
-----------------	--

End point description:

Antibody GMC as measured in mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were presented. Evaluable immunogenicity population: had treatments as randomized at all 4 doses, blood drawn within specified timeframes, had at least 1 valid and determinate assay result for the proposed analysis, and no major protocol violations. n=number of subjects with determinate IgG antibody concentration for the specified serotype.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

1 month after toddler dose (13 months of age)

End point values	13vPnC: Toddler Dose	7vPnC: Toddler Dose		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	193	196		
Units: mcg/mL				
geometric mean (confidence interval 95%)				
Common serotypes - serotype 4 (n=193, 196)	5.33 (4.69 to 6.04)	5.85 (5.13 to 6.68)		

Common serotypes - serotype 6B (n= 192, 195)	12.24 (10.6 to 14.13)	11.6 (9.95 to 13.53)		
Common serotypes - serotype 9V (n= 193,196)	3.01 (2.68 to 3.37)	3.33 (2.96 to 3.75)		
Common serotypes - serotype 14 (n= 193,196)	10.59 (9.21 to 12.18)	10.95 (9.41 to 12.74)		
Common serotypes - serotype 18C (n= 193,196)	2.63 (2.33 to 2.97)	2.98 (2.65 to 3.34)		
Common serotypes - serotype 19F (n= 193,196)	8.38 (7.11 to 9.87)	5.65 (4.84 to 6.58)		
Common serotypes - serotype 23F (n= 193,196)	4.27 (3.66 to 4.98)	5.31 (4.66 to 6.04)		
Additional serotypes - serotype 1 (n= 193,195)	5.1 (4.39 to 5.92)	0.04 (0.04 to 0.05)		
Additional serotypes - serotype 3 (n= 193,194)	0.91 (0.81 to 1.03)	0.09 (0.08 to 0.11)		
Additional serotypes - serotype 5 (n= 192,183)	3.58 (3.2 to 4)	0.64 (0.55 to 0.75)		
Additional serotypes - serotype 6A (n= 193,194)	8.13 (7.11 to 9.28)	1.87 (1.62 to 2.17)		
Additional serotypes - serotype 7F (n= 193,194)	4.81 (4.27 to 5.42)	0.06 (0.05 to 0.08)		
Additional serotypes - serotype 19A (n= 193,194)	14.12 (12.45 to 16.01)	3.56 (3.14 to 4.05)		

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Percentage of Subjects With Pre-specified Local Reactions: Infant Series Dose 1 (6 Weeks of Age)

End point title	Percentage of Subjects With Pre-specified Local Reactions: Infant Series Dose 1 (6 Weeks of Age)
-----------------	--

End point description:

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeter [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (greater than [ $>$ ] 7.0 cm). Subjects may be represented in more than 1 category. Safety population: all subjects who received dose 1 of the infant series vaccination (6 weeks of age). n= number of subjects reporting yes for at least 1 day or no for all days for each treatment group respectively.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after the dose 1 of the infant series (6 weeks of age)

End point values	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	353	353		
Units: Percentage of subjects				
number (not applicable)				
Tenderness: Any (n= 347,347)	62.5	59.7		

Tenderness: Significant (n= 341,343)	42.2	40.5		
Induration: Any (n= 339,342)	21.5	22.5		
Induration: Mild (n= 338,340)	19.2	19.1		
Induration: Moderate (n= 331,338)	4.8	5.6		
Induration: Severe (n= 329,336)	0	0		
Erythema: Any (n= 333,339)	12.6	13.3		
Erythema: Mild (n= 333,338)	11.4	11.8		
Erythema: Moderate (n= 330,337)	1.5	1.8		
Erythema: Severe (n= 329,336)	0	0		
Any of the above (n= 349,348)	66.8	65.2		

## Statistical analyses

Statistical analysis title	Tenderness-any
----------------------------	----------------

Statistical analysis description:

Difference in incidence rates of tenderness-any within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.483
Method	Fisher exact

Statistical analysis title	Tenderness-significant
----------------------------	------------------------

Statistical analysis description:

Difference in incidence rates of tenderness-significant within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.698
Method	Fisher exact

Statistical analysis title	Induration-any
----------------------------	----------------

Statistical analysis description:

Difference in incidence rates of induration-any within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
-------------------	--

Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.782
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-mild
-----------------------------------	-----------------

Statistical analysis description:

Difference in incidence rates of induration-mild within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-moderate
-----------------------------------	---------------------

Statistical analysis description:

Difference in incidence rates of induration-moderate within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.729
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-severe
-----------------------------------	-------------------

Statistical analysis description:

Difference in incidence rates of Induration-Severe within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 <sup>[3]</sup>
Method	Fisher exact

Notes:

[3] - Here, "99999" in the p-value signifies not applicable, since no severe induration in both groups.

<b>Statistical analysis title</b>	Erythema-any
-----------------------------------	--------------



---

**Statistical analysis description:**

Difference in incidence rates of Erythema-Any within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.819
Method	Fisher exact

---

**Statistical analysis title**

Erythema-mild

---

**Statistical analysis description:**

Difference in incidence rates of erythema-mild within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.904
Method	Fisher exact

---

**Statistical analysis title**

Erythema-moderate

---

**Statistical analysis description:**

Difference in incidence rates of Erythema-Moderate within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

---

**Statistical analysis title**

Erythema-severe

---

**Statistical analysis description:**

Difference in incidence rates of erythema-severe within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
-------------------	--

Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 [4]
Method	Fisher exact

Notes:

[4] - Here, "99999" in the p-value signifies not applicable, since no severe erythema in both groups".

<b>Statistical analysis title</b>	Any local reaction
-----------------------------------	--------------------

Statistical analysis description:

Difference in incidence rates of any local reaction (tenderness, induration and erythema) within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.69
Method	Fisher exact

#### **Other pre-specified: Percentage of Subjects With Pre-specified Local Reactions: Infant Series Dose 2 (10 Weeks of Age)**

End point title	Percentage of Subjects With Pre-specified Local Reactions: Infant Series Dose 2 (10 Weeks of Age)
-----------------	---

End point description:

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Subjects may be represented in more than 1 category. Safety population: all subjects who received the first 2 doses of the infant series vaccination (10 weeks of age). n= number of subjects reporting yes for at least 1 day or no for all days for each treatment group respectively.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after the dose 2 of the infant series (10 weeks of age)

<b>End point values</b>	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	300	300		
Units: Percentage of subjects				
number (not applicable)				
Tenderness: Any (n= 284,282)	44.4	44		
Tenderness: Significant (n= 278,279)	26.6	28		
Induration: Any (n= 281,278)	20.6	18.7		
Induration: Mild (n= 281,277)	16.7	16.2		
Induration: Moderate (n= 273,272)	5.1	4		
Induration: Severe (n= 273,271)	0	0		
Erythema: Any (n= 275,280)	13.8	17.9		

Erythema: Mild (n= 275,279)	13.1	15.8		
Erythema: Moderate (n= 273,273)	1.5	2.9		
Erythema: Severe (n= 273,271)	0	0		
Any of the above (n= 285,286)	51.6	53.1		

## Statistical analyses

<b>Statistical analysis title</b>	Tenderness-any
-----------------------------------	----------------

Statistical analysis description:

Difference in incidence rates of tenderness-any within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.933
Method	Fisher exact

<b>Statistical analysis title</b>	Tenderness-significant
-----------------------------------	------------------------

Statistical analysis description:

Difference in incidence rates of tenderness-significant within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.776
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-any
-----------------------------------	----------------

Statistical analysis description:

Difference in incidence rates of induration-any within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.596
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-mild
Statistical analysis description:	
Difference in incidence rates of induration-mild within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.909
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-moderate
Statistical analysis description:	
Difference in incidence rates of induration-moderate within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.683
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-severe
Statistical analysis description:	
Difference in incidence rates of induration-severe within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 [5]
Method	Fisher exact

Notes:

[5] - Here, "99999" in the p-value signifies not applicable, since no severe induration in both groups.

<b>Statistical analysis title</b>	Erythema-any
Statistical analysis description:	
Difference in incidence rates of erythema-any within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series

Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.203
Method	Fisher exact

<b>Statistical analysis title</b>	Erythema-mild
-----------------------------------	---------------

Statistical analysis description:

Difference in incidence rates of Erythema-Mild within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.399
Method	Fisher exact

<b>Statistical analysis title</b>	Erythema-moderate
-----------------------------------	-------------------

Statistical analysis description:

Difference in incidence rates of erythema-moderate within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.382
Method	Fisher exact

<b>Statistical analysis title</b>	Erythema-severe
-----------------------------------	-----------------

Statistical analysis description:

Difference in incidence rates of erythema-severe within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 [6]
Method	Fisher exact

Notes:

[6] - Here, "99999" in the p-value signifies not applicable, since no severe erythema in both groups.

<b>Statistical analysis title</b>	Any local reaction
-----------------------------------	--------------------

**Statistical analysis description:**

Difference in incidence rates of any Local reaction (tenderness, induration, erythema) within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.738
Method	Fisher exact

**Other pre-specified: Percentage of Subjects With Pre-specified Local Reactions: Infant Series Dose 3 (14 Weeks of Age)**

End point title	Percentage of Subjects With Pre-specified Local Reactions: Infant Series Dose 3 (14 Weeks of Age)
-----------------	---

**End point description:**

Local reactions were reported using an electronic diary by the parent/legal guardian. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration and erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Subjects may be represented in more than 1 category. Safety population: all subjects who received all 3 doses of the infant series vaccination (14 weeks of age). n= number of subjects reporting yes for at least 1 day or no for all days for each treatment group respectively.

End point type	Other pre-specified
----------------	---------------------

**End point timeframe:**

Within 4 days after the dose 3 of the infant series (14 weeks of age)

<b>End point values</b>	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	221	218		
Units: Percentage of subjects				
number (not applicable)				
Tenderness: Any (n= 204,200)	37.3	38		
Tenderness: Significant (n= 199,196)	24.1	23.5		
Induration: Any (n= 198,195)	17.2	13.8		
Induration: Mild (n= 196,195)	15.8	11.8		
Induration: Moderate (n= 193,193)	2.6	3.6		
Induration: Severe (n= 191,193)	0	0		
Erythema: Any (n= 192,195)	10.4	9.7		
Erythema: Mild (n= 192,195)	10.4	9.2		
Erythema: Moderate (n= 191,193)	0	0.5		
Erythema: Severe (n= 191,193)	0	0		
Any of the above (n= 206,202)	43.2	42.1		

**Statistical analyses**

<b>Statistical analysis title</b>	Tenderness-any
Statistical analysis description:	
Difference in incidence rates of tenderness-any within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.918
Method	Fisher exact

<b>Statistical analysis title</b>	Tenderness-significant
Statistical analysis description:	
Difference in incidence rates of tenderness-significant within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.906
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-any
Statistical analysis description:	
Difference in incidence rates of induration-any within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.404
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-mild
Statistical analysis description:	
Difference in incidence rates of induration-mild within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series

Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.305
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-moderate
-----------------------------------	---------------------

Statistical analysis description:

Difference in incidence rates of induration-moderate within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.771
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-severe
-----------------------------------	-------------------

Statistical analysis description:

Difference in incidence rates of induration-severe within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 [7]
Method	Fisher exact

Notes:

[7] - Here, "99999" in the p-value signifies not applicable, since no severe induration in both groups.

<b>Statistical analysis title</b>	Erythema-any
-----------------------------------	--------------

Statistical analysis description:

Difference in incidence rates of erythema-any within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.867
Method	Fisher exact

<b>Statistical analysis title</b>	Erythema-mild
-----------------------------------	---------------



---

**Statistical analysis description:**

Difference in incidence rates of erythema-mild within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.735
Method	Fisher exact

---

**Statistical analysis title**

Erythema-moderate

---

**Statistical analysis description:**

Difference in incidence rates of erythema-moderate within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

---

**Statistical analysis title**

Erythema-severe

---

**Statistical analysis description:**

Difference in incidence rates of erythema-severe within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 [8]
Method	Fisher exact

---

**Notes:**

[8] - Here, "99999" in the p-value signifies not applicable, since no severe erythema in both groups.

---

**Statistical analysis title**

Any local reaction

---

**Statistical analysis description:**

Difference in incidence rates of any Local Reaction (tenderness, induration, erythema) within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
-------------------	--

Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.842
Method	Fisher exact

### Other pre-specified: Percentage of Subjects With Pre-specified Local Reactions: Toddler Dose (12 Months of Age)

End point title	Percentage of Subjects With Pre-specified Local Reactions: Toddler Dose (12 Months of Age)
-----------------	--

#### End point description:

Local reactions were reported using an electronic diary by the parent/legal guardian. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration and erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Subjects may be represented in more than 1 category. Safety population: all subjects who received toddler dose vaccination(after 12 months). n= number of subjects reporting yes for at least 1 day or no for all days for each treatment group respectively.

End point type	Other pre-specified
----------------	---------------------

#### End point timeframe:

Within 4 days after the toddler dose (12 months of age)

End point values	13vPnC: Toddler Dose	7vPnC: Toddler Dose		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	198	200		
Units: Percentage of subjects				
number (not applicable)				
Tenderness: Any (n= 174,176)	29.9	30.7		
Tenderness: Significant (n= 171,170)	15.8	17.1		
Induration: Any (n= 173,176)	19.7	17.6		
Induration: Mild (n= 170,175)	15.9	14.9		
Induration: Moderate (n= 170,171)	5.3	7.6		
Induration: Severe (n= 167,169)	0	0		
Erythema: Any (n= 174,176)	14.9	14.2		
Erythema: Mild (n= 172,175)	12.2	10.9		
Erythema: Moderate (n= 169,170)	3.6	4.1		
Erythema: Severe (n= 167,169)	0	0		
Any of the above (n= 177,178)	36.7	41		

### Statistical analyses

Statistical analysis title	Tenderness-any
----------------------------	----------------

#### Statistical analysis description:

Difference in incidence rates of tenderness-any within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.908
Method	Fisher exact

<b>Statistical analysis title</b>	Tenderness-significant
-----------------------------------	------------------------

Statistical analysis description:

Difference in incidence rates of tenderness-significant within 4 days of the toddler dose, dose 4(12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.772
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-any
-----------------------------------	----------------

Statistical analysis description:

Difference in incidence rates of induration-any within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.681
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-mild
-----------------------------------	-----------------

Statistical analysis description:

Difference in incidence rates of induration-mild within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.881
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-moderate
Statistical analysis description:	
Difference in incidence rates of induration-moderate within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.509
Method	Fisher exact

<b>Statistical analysis title</b>	Induration-severe
Statistical analysis description:	
Difference in incidence rates of induration-severe within 4 days of the toddler dose (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 [9]
Method	Fisher exact

Notes:

[9] - Here, "99999" in the p-value signifies not applicable, since no severe induration in both groups.

<b>Statistical analysis title</b>	Erythema-any
Statistical analysis description:	
Difference in incidence rates of erythema-any within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.88
Method	Fisher exact

<b>Statistical analysis title</b>	Erythema-mild
Statistical analysis description:	
Difference in incidence rates of erythema-mild within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose

Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.739
Method	Fisher exact

<b>Statistical analysis title</b>	Erythema-moderate
-----------------------------------	-------------------

Statistical analysis description:

Difference in incidence rates of erythema-moderate within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

<b>Statistical analysis title</b>	Erythema-severe
-----------------------------------	-----------------

Statistical analysis description:

Difference in incidence rates of erythema-severe within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 [10]
Method	Fisher exact

Notes:

[10] - Here, "99999" in the p-value signifies not applicable, since no severe erythema in both groups.

<b>Statistical analysis title</b>	Any local reaction
-----------------------------------	--------------------

Statistical analysis description:

Difference in incidence rates of any local reaction (tenderness, induration, erythema) within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.446
Method	Fisher exact

## Other pre-specified: Percentage of Subjects With Pre-specified Systemic Events:

**Infant Series Dose 1 (6 Weeks of Age)**

End point title	Percentage of Subjects With Pre-specified Systemic Events: Infant Series Dose 1 (6 Weeks of Age)
-----------------	--

End point description:

Systemic events (any fever  $\geq 38$  degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Subjects may be represented in more than 1 category. Safety population: all subjects who received at least dose 1 of the infant series vaccination (after 6 weeks). n=number of subjects reporting yes for at least 1 day or no for all days for each treatment group respectively.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after the dose 1 of the infant series (6 weeks of age)

End point values	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	353	353		
Units: Percentage of subjects				
number (not applicable)				
Fever $\geq 38$ but $\leq 39$ degrees C (n= 313,324)	19.8	21.6		
Fever $> 39$ but $\leq 40$ degrees C (n= 309,322)	2.3	1.2		
Fever $> 40$ degrees C (n= 309,322)	0.3	0.9		
Decreased appetite (n= 343,347)	55.7	55.9		
Irritability (n= 345,347)	83.2	79.8		
Increased sleep (n= 338,342)	40.8	36.8		
Decreased sleep (n= 336,343)	55.7	56		
Any systemic event (n= 350,348)	94.3	90.8		

**Statistical analyses**

<b>Statistical analysis title</b>	Fever $\geq 38$ but $\leq 39$ degrees C
Statistical analysis description:	
Difference in incidence rates of fever $\geq 38$ but less than or equal to ( $\leq$ ) 39 degrees C within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.625
Method	Fisher exact

<b>Statistical analysis title</b>	Fever $> 39$ but $\leq 40$ degrees C
-----------------------------------	--------------------------------------

Statistical analysis description:

Difference in incidence rates of fever  $> 39$  but  $\leq 40$  degrees C within 4 days of the infant series dose 1

(6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.375
Method	Fisher exact

<b>Statistical analysis title</b>	Fever >40 degrees C
-----------------------------------	---------------------

Statistical analysis description:

Difference in incidence rates of fever >40 degrees C within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.624
Method	Fisher exact

<b>Statistical analysis title</b>	Decreased appetite
-----------------------------------	--------------------

Statistical analysis description:

Difference in incidence rates of decreased appetite within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

<b>Statistical analysis title</b>	Irritability
-----------------------------------	--------------

Statistical analysis description:

Difference in incidence rates of irritability within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.282
Method	Fisher exact

<b>Statistical analysis title</b>	Increased sleep
Statistical analysis description: Difference in incidence rates of Increased sleep within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.307
Method	Fisher exact

<b>Statistical analysis title</b>	Decreased sleep
Statistical analysis description: Difference in incidence rates of decreased sleep within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.939
Method	Fisher exact

<b>Statistical analysis title</b>	Any systemic event
Statistical analysis description: Difference in incidence rates of any systemic event (fever, decrease in appetite, irritability, increased or decreased sleep) within 4 days of the infant series dose 1 (6 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	706
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.085
Method	Fisher exact

#### **Other pre-specified: Percentage of Subjects With Pre-specified Systemic Events: Infant Series Dose 2 (10 Weeks of Age)**

End point title	Percentage of Subjects With Pre-specified Systemic Events: Infant Series Dose 2 (10 Weeks of Age)
-----------------	---

End point description:

Systemic events (any fever  $\geq 38$  degrees C, decreased appetite, irritability, increased sleep, decreased



sleep) were reported using an electronic diary. Subjects may be represented in more than 1 category. Safety population: all subjects who received dose 2 of the infant series vaccination (10 weeks of age); n= number of subjects reporting yes for at least 1 day or no for all days for each treatment group respectively.

End point type	Other pre-specified
End point timeframe:	
Within 4 days after the dose 2 of the infant series (10 weeks of age)	

End point values	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	300	300		
Units: Percentage of subjects				
number (not applicable)				
Fever $\geq 38$ but $\leq 39$ degrees C (n= 263,249)	10.3	15.3		
Fever $> 39$ but $\leq 40$ degrees C (n= 259,247)	0.8	0.4		
Fever $> 40$ degrees C (n= 259,247)	0	0.4		
Decreased appetite (n= 281,282)	48	46.5		
Irritability (n= 290,291)	70.7	69.8		
Increased sleep (n= 285,275)	33.7	26.9		
Decreased sleep (n= 282,286)	37.9	46.9		
Any systemic event (n= 294,297)	80.6	80.5		

## Statistical analyses

<b>Statistical analysis title</b>	Fever $\geq 38$ but $\leq 39$ degrees C
Statistical analysis description:	
Difference in incidence rates of fever $\geq 38$ but $\leq 39$ degrees C within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.111
Method	Fisher exact

<b>Statistical analysis title</b>	Fever $> 39$ but $\leq 40$ degrees C
Statistical analysis description:	
Difference in incidence rates of fever $> 39$ but $\leq 40$ degrees C within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series

Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

<b>Statistical analysis title</b>	Fever >40 degrees C
-----------------------------------	---------------------

Statistical analysis description:

Difference in incidence rates of fever >40 degrees C within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.488
Method	Fisher exact

<b>Statistical analysis title</b>	Decreased appetite
-----------------------------------	--------------------

Statistical analysis description:

Difference in incidence rates of Decreased appetite within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.736
Method	Fisher exact

<b>Statistical analysis title</b>	Irritability
-----------------------------------	--------------

Statistical analysis description:

Difference in incidence rates of Irritability within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.856
Method	Fisher exact

<b>Statistical analysis title</b>	Increased sleep
-----------------------------------	-----------------

---

**Statistical analysis description:**

Difference in incidence rates of Increased sleep within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.098
Method	Fisher exact

---

**Statistical analysis title**

Decreased sleep

---

**Statistical analysis description:**

Difference in incidence rates of Decreased sleep within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.034
Method	Fisher exact

---

**Statistical analysis title**

Any systemic event

---

**Statistical analysis description:**

Difference in incidence rates of Any systemic event (fever, decrease in appetite, irritability, increased or decreased sleep) within 4 days of the infant series dose 2 (10 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	600
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

---

**Other pre-specified: Percentage of Subjects With Pre-specified Systemic Events: Infant Series Dose 3 (14 Weeks of Age)**

End point title	Percentage of Subjects With Pre-specified Systemic Events: Infant Series Dose 3 (14 Weeks of Age)
-----------------	---

---

**End point description:**

Systemic events (any fever  $\geq 38$  degrees C, decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Subjects may be represented in more than 1 category. Safety population: all subjects who received dose 3 of the infant series vaccination (14 weeks of age). n= number of subjects reporting yes for at least 1 day or no for all days for each treatment group respectively.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after the dose 3 of the infant series (14 weeks of age)

End point values	13vPnC: Infant series	7vPnC: Infant Series		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	221	218		
Units: Percentage of subjects				
number (not applicable)				
Fever $\geq 38$ but $\leq 39$ degrees C (n= 181,172)	7.7	14		
Fever $> 39$ but $\leq 40$ degrees C (n= 179,170)	0	0		
Fever $> 40$ degrees C (n= 179,171)	0	0.6		
Decreased appetite (n= 202,200)	42.1	41		
Irritability (n= 208,208)	64.4	67.3		
Increased sleep (n= 199,195)	20.1	20.5		
Decreased sleep (n= 205,201)	42.4	36.8		
Any systemic event (n= 213,209)	75.1	78.5		

## Statistical analyses

<b>Statistical analysis title</b>	Fever $\geq 38$ but $\leq 39$ degrees C
Statistical analysis description: Difference in incidence rates of fever $\geq 38$ but $\leq 39$ degrees C within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.085
Method	Fisher exact

<b>Statistical analysis title</b>	Fever $> 39$ but $\leq 40$ degrees C
Statistical analysis description: Difference in incidence rates of fever $> 39$ but $\leq 40$ degrees C within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series

Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 <sup>[11]</sup>
Method	Fisher exact

Notes:

[11] - Here, "99999" in the p-value signifies not applicable, since no subject with fever > 39 but <= 40 degrees C in both groups.

<b>Statistical analysis title</b>	Fever >40 degrees C
-----------------------------------	---------------------

Statistical analysis description:

Difference in incidence rates of fever >40 degrees C within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.489
Method	Fisher exact

<b>Statistical analysis title</b>	Decreased appetite
-----------------------------------	--------------------

Statistical analysis description:

Difference in incidence rates of decreased appetite within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.84
Method	Fisher exact

<b>Statistical analysis title</b>	Irritability
-----------------------------------	--------------

Statistical analysis description:

Difference in incidence rates of irritability within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.605
Method	Fisher exact

<b>Statistical analysis title</b>	Increased sleep
-----------------------------------	-----------------

---

**Statistical analysis description:**

Difference in incidence rates of increased sleep within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

---

**Statistical analysis title**

Decreased sleep

---

**Statistical analysis description:**

Difference in incidence rates of decreased sleep within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.265
Method	Fisher exact

---

**Statistical analysis title**

Any systemic event

---

**Statistical analysis description:**

Difference in incidence rates of any systemic event (fever, decrease in appetite, irritability, increased or decreased sleep) within 4 days of the infant series dose 3 (14 weeks of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Infant series v 7vPnC: Infant Series
Number of subjects included in analysis	439
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.422
Method	Fisher exact

---

**Other pre-specified: Percentage of Subjects With Pre-specified Systemic Events: Toddler Dose (12 Months of Age)**

End point title	Percentage of Subjects With Pre-specified Systemic Events: Toddler Dose (12 Months of Age)
-----------------	--

---

**End point description:**

Systemic events (any fever  $\geq 38$  degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Subjects may be represented in more than 1 category. Safety population: all subjects who received toddler dose vaccination (12 months of age).n= number of subjects reporting yes for at least 1 day or no for all days for each treatment group respectively.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after the toddler dose(12 months of age)

End point values	13vPnC: Toddler Dose	7vPnC: Toddler Dose		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	198	200		
Units: Percentage of subjects				
number (not applicable)				
Fever $\geq 38$ but $\leq 39$ degrees C (n= 161,154)	5.6	6.5		
Fever $> 39$ but $\leq 40$ degrees (n= 160,152)	0.6	0		
Fever $> 40$ degrees C (n= 160,152)	0	0		
Decreased appetite (n= 174,179)	28.7	24.6		
Irritability (n= 174,183)	38.5	35		
Increased sleep (n= 171,170)	12.3	9.4		
Decreased sleep (n= 172,178)	22.7	27		
Any systemic event (n= 179,186)	54.7	52.7		

## Statistical analyses

<b>Statistical analysis title</b>	Fever $\geq 38$ but $\leq 39$ degrees C
Statistical analysis description: Difference in incidence rates of fever $\geq 38$ but $\leq 39$ degrees within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.815
Method	Fisher exact

<b>Statistical analysis title</b>	Fever $> 39$ but $\leq 40$ degrees C
Statistical analysis description: Difference in incidence rates of fever $> 39$ but $\leq 40$ degrees within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.	
Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose

Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.99
Method	Fisher exact

<b>Statistical analysis title</b>	Fever >40 degrees C
-----------------------------------	---------------------

Statistical analysis description:

Difference in incidence rates of fever >40 degrees C within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 99999 [12]
Method	Fisher exact

Notes:

[12] - Here, "99999" in the p-value signifies not applicable, since no subject with fever > 40 degrees C in both groups.

<b>Statistical analysis title</b>	Decreased appetite
-----------------------------------	--------------------

Statistical analysis description:

Difference in incidence rates of decreased appetite within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.401
Method	Fisher exact

<b>Statistical analysis title</b>	Irritability
-----------------------------------	--------------

Statistical analysis description:

Difference in incidence rates of irritability within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.511
Method	Fisher exact

<b>Statistical analysis title</b>	Increased sleep
-----------------------------------	-----------------



---

**Statistical analysis description:**

Difference in incidence rates of increased sleep within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.487
Method	Fisher exact

---

**Statistical analysis title**

Decreased sleep

---

**Statistical analysis description:**

Difference in incidence rates of decreased sleep within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.388
Method	Fisher exact

---

**Statistical analysis title**

Any systemic event

---

**Statistical analysis description:**

Difference in incidence rates of any systemic event fever, decrease in appetite, irritability, increased or decreased sleep) within 4 days of the toddler dose, dose 4 (12 months of age) reported in the 13vPnC group relative to the incidence rates in the 7vPnC group. No hypothesis testing was performed. The analysis is descriptive.

Comparison groups	13vPnC: Toddler Dose v 7vPnC: Toddler Dose
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.753
Method	Fisher exact

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AEs were recorded from signing of ICF to 1 month after infant series and toddler dose to 1 month after toddler dose. SAEs were recorded from signing of ICF to 1 month after toddler dose. Local and systemic events assessed within 4 days of each vaccination

Adverse event reporting additional description:

Safety population = all randomized subjects with at least 1 dose of study treatment. An Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may = serious for 1 subject and = non-serious for another subject or subject may have experienced both a serious and non-serious episode of the same event.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	12.1
--------------------	------

### Reporting groups

Reporting group title	Infant Series 13vPnC
-----------------------	----------------------

Reporting group description:

Subjects received 1 single 0.5 mL dose of 13vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series), co-administered with a commercially available combination vaccine containing DTP-Hib-HBV and a commercially available OPV.

Reporting group title	Infant Series 7vPnC
-----------------------	---------------------

Reporting group description:

Subjects received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series), co-administered with a commercially available combination vaccine containing DTP-Hib-HBV and a commercially available OPV.

Reporting group title	After the Infant Series 13vPnC
-----------------------	--------------------------------

Reporting group description:

Subjects received 1 single 0.5 mL dose of 13vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series), co-administered with a commercially available combination vaccine DTP-Hib-HBV and a commercially available OPV. AEs were collected from approximately 1 month after Dose 3 to the Toddler dose.

Reporting group title	After the Infant Series 7vPnC
-----------------------	-------------------------------

Reporting group description:

Subjects received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 6, 10 and 14 weeks of age (infant series), co-administered with a commercially available combination vaccine containing DTP-Hib-HBV and a commercially available OPV. AEs were collected from approximately 1 month after Dose 3 to the Toddler dose.

Reporting group title	Toddler Dose 13vPnC
-----------------------	---------------------

Reporting group description:

Subjects received 1 single 0.5 mL dose of 13vPnC, administered intramuscularly, at 12 months of age (toddler dose).

Reporting group title	Toddler Dose 7vPnC
-----------------------	--------------------

Reporting group description:

Subjects received 1 single 0.5 mL dose of 7vPnC, administered intramuscularly, at 12 months of age (toddler dose).

Serious adverse events	Infant Series 13vPnC	Infant Series 7vPnC	After the Infant Series 13vPnC
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 353 (2.27%)	6 / 353 (1.70%)	8 / 353 (2.27%)

number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute lymphocytic leukaemia			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	1 / 353 (0.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pneumonitis			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breath holding			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Heart disease congenital			

subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	1 / 353 (0.28%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	1 / 353 (0.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	1 / 353 (0.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Infantile colic			

subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatosplenomegaly			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	1 / 353 (0.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Drug eruption			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchiolitis			
subjects affected / exposed	2 / 353 (0.57%)	4 / 353 (1.13%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	3 / 353 (0.85%)	0 / 353 (0.00%)	1 / 353 (0.28%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Viral infection			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	1 / 353 (0.28%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	1 / 353 (0.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	2 / 353 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	2 / 353 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	2 / 353 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysentery			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	1 / 353 (0.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral myocarditis			

subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Hypocalcaemia			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Dehydration</b>			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	2 / 353 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	After the Infant Series 7vPnC	Toddler Dose 13vPnC	Toddler Dose 7vPnC
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	11 / 353 (3.12%)	4 / 198 (2.02%)	1 / 200 (0.50%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
Acute lymphocytic leukaemia			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>General disorders and administration site conditions</b>			
Pyrexia			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
Pneumonitis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			

subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 353 (0.00%)	1 / 198 (0.51%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breath holding			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	1 / 200 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Heart disease congenital			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			



subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Infantile colic			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatosplenomegaly			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Drug eruption			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchiolitis			

subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	1 / 353 (0.28%)	1 / 198 (0.51%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	4 / 353 (1.13%)	2 / 198 (1.01%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			

subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysentery			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral myocarditis			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypocalcaemia			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Infant Series 13vPnC	Infant Series 7vPnC	After the Infant Series 13vPnC
Total subjects affected by non-serious adverse events subjects affected / exposed	330 / 353 (93.48%)	316 / 353 (89.52%)	5 / 353 (1.42%)
Vascular disorders Pallor subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Pregnancy, puerperium and perinatal conditions Umbilical granuloma subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
General disorders and administration site conditions Injection site pain subjects affected / exposed occurrences (all)  Injection site swelling subjects affected / exposed occurrences (all)  Pyrexia subjects affected / exposed occurrences (all)  Injection site erythema subjects affected / exposed occurrences (all)  Injection site nodule subjects affected / exposed occurrences (all)  Irritability subjects affected / exposed occurrences (all)  Tenderness subjects affected / exposed occurrences (all)  Fever ≥38°C but ≤39°C Infant Series Dose 1 and Toddler Dose alternative dictionary used: Systemic Events 0.0	75 / 353 (21.25%) 131  55 / 353 (15.58%) 89  29 / 353 (8.22%) 31  12 / 353 (3.40%) 15  5 / 353 (1.42%) 5  1 / 353 (0.28%) 1  0 / 353 (0.00%) 0	70 / 353 (19.83%) 118  57 / 353 (16.15%) 83  21 / 353 (5.95%) 22  12 / 353 (3.40%) 14  12 / 353 (3.40%) 12  3 / 353 (0.85%) 3  1 / 353 (0.28%) 1	0 / 353 (0.00%) 0  0 / 353 (0.00%) 0  0 / 353 (0.00%) 0  0 / 353 (0.00%) 0  0 / 353 (0.00%) 0  0 / 353 (0.00%) 0  0 / 353 (0.00%) 0
Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.			

<p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[1]</sup></p> <p>occurrences (all)</p>	<p>62 / 313 (19.81%)</p> <p>62</p>	<p>70 / 324 (21.60%)</p> <p>70</p>	<p>0 / 353 (0.00%)</p> <p>0</p>
<p>Fever &gt;39°C but ≤40°C Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[2]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
	<p>7 / 309 (2.27%)</p> <p>7</p>	<p>4 / 322 (1.24%)</p> <p>4</p>	<p>0 / 353 (0.00%)</p> <p>0</p>
<p>Fever &gt;40°C Dose Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[3]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
	<p>1 / 309 (0.32%)</p> <p>1</p>	<p>3 / 322 (0.93%)</p> <p>3</p>	<p>0 / 353 (0.00%)</p> <p>0</p>
<p>Decreased appetite Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[4]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
	<p>191 / 343 (55.69%)</p> <p>191</p>	<p>194 / 347 (55.91%)</p> <p>194</p>	<p>0 / 353 (0.00%)</p> <p>0</p>
<p>Irritability Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[5]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
	<p>287 / 345 (83.19%)</p> <p>287</p>	<p>277 / 347 (79.83%)</p> <p>277</p>	<p>0 / 353 (0.00%)</p> <p>0</p>
<p>Increased sleep Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[6]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
	<p>138 / 338 (40.83%)</p> <p>138</p>	<p>126 / 342 (36.84%)</p> <p>126</p>	<p>0 / 353 (0.00%)</p> <p>0</p>
<p>Decreased sleep Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Systemic Events 0.0</p>	<p>Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		

alternative assessment type: Systematic subjects affected / exposed <sup>[7]</sup> occurrences (all)	187 / 336 (55.65%) 187	192 / 343 (55.98%) 192	0 / 353 (0.00%) 0
Fever ≥38°C but ≤39°C Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[8]</sup> occurrences (all)	27 / 263 (10.27%) 27	38 / 249 (15.26%) 38	0 / 353 (0.00%) 0
Fever >39°C but ≤40°C Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[9]</sup> occurrences (all)	2 / 259 (0.77%) 2	1 / 247 (0.40%) 1	0 / 353 (0.00%) 0
Decreased appetite Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[10]</sup> occurrences (all)	135 / 281 (48.04%) 135	131 / 282 (46.45%) 131	0 / 353 (0.00%) 0
Fever >40°C Dose Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[11]</sup> occurrences (all)	0 / 259 (0.00%) 0	1 / 247 (0.40%) 1	0 / 353 (0.00%) 0
Irritability Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[12]</sup> occurrences (all)	205 / 290 (70.69%) 205	203 / 291 (69.76%) 203	0 / 353 (0.00%) 0
Increased sleep Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used:			

# Systemic Events 0.0

alternative assessment type:  
Systematic

subjects affected / exposed<sup>[13]</sup>

occurrences (all)

96 / 285 (33.68%)

96

74 / 275 (26.91%)

74

0 / 353 (0.00%)

0

## Decreased sleep Infant Series Dose 2

Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.

alternative dictionary used:  
Systemic Events 0.0

alternative assessment type:  
Systematic

subjects affected / exposed<sup>[14]</sup>

occurrences (all)

107 / 282 (37.94%)

107

134 / 286 (46.85%)

134

0 / 353 (0.00%)

0

## Fever ≥38°C but ≤39°C Infant Series Dose 3

Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.

alternative dictionary used:  
Systemic Events 0.0

alternative assessment type:  
Systematic

subjects affected / exposed<sup>[15]</sup>

occurrences (all)

14 / 181 (7.73%)

14

24 / 172 (13.95%)

24

0 / 353 (0.00%)

0

## Fever >40°C Dose Infant Series Dose 3

Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.

alternative dictionary used:  
Systemic Events 0.0

alternative assessment type:  
Systematic

subjects affected / exposed<sup>[16]</sup>

occurrences (all)

0 / 179 (0.00%)

0

1 / 171 (0.58%)

1

0 / 353 (0.00%)

0

## Decreased appetite Infant Series Dose 3

Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.

alternative dictionary used:  
Systemic Events 0.0

alternative assessment type:  
Systematic

subjects affected / exposed<sup>[17]</sup>

occurrences (all)

85 / 202 (42.08%)

85

82 / 200 (41.00%)

82

0 / 353 (0.00%)

0

## Irritability Infant Series Dose 3

Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.

alternative dictionary used:  
Systemic Events 0.0

alternative assessment type:  
Systematic

subjects affected / exposed<sup>[18]</sup>

occurrences (all)

134 / 208 (64.42%)

134

140 / 208 (67.31%)

140

0 / 353 (0.00%)

0

## Increased sleep Infant Series Dose 3

Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.

alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[19]</sup> occurrences (all)	40 / 199 (20.10%) 40	40 / 195 (20.51%) 40	0 / 353 (0.00%) 0
Decreased sleep Infant Series Dose 3 alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[20]</sup> occurrences (all)	Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
87 / 205 (42.44%) 87	74 / 201 (36.82%) 74	0 / 353 (0.00%) 0	
Immune system disorders Allergy to arthropod bite subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Reproductive system and breast disorders Penile adhesion subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	37 / 353 (10.48%) 41	40 / 353 (11.33%) 49	0 / 353 (0.00%) 0
Upper airway obstruction subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	3 / 353 (0.85%) 3	0 / 353 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Productive cough subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Wheezing subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Bronchial hyperreactivity			



subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Asthma subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Injury, poisoning and procedural complications Head injury subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Congenital, familial and genetic disorders Macrocephaly subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Phimosis subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Cardiac disorders Ventricular extrasystoles subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Nervous system disorders Crying subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Convulsion subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0

Somnolence subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Otorrhoea subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Eye disorders Eye discharge subjects affected / exposed occurrences (all)	2 / 353 (0.57%) 2	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Lacrimation increased subjects affected / exposed occurrences (all)	2 / 353 (0.57%) 2	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 353 (0.28%) 1	0 / 353 (0.00%) 0
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	21 / 353 (5.95%) 24	26 / 353 (7.37%) 29	1 / 353 (0.28%) 1
Vomiting subjects affected / exposed occurrences (all)	4 / 353 (1.13%) 4	6 / 353 (1.70%) 6	0 / 353 (0.00%) 0

Constipation			
subjects affected / exposed	1 / 353 (0.28%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	1	1	0
Infantile colic			
subjects affected / exposed	2 / 353 (0.57%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	3	0	0
Abdominal discomfort			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Perianal erythema			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	2 / 353 (0.57%)	2 / 353 (0.57%)	0 / 353 (0.00%)
occurrences (all)	2	2	0
Seborrhoeic dermatitis			
subjects affected / exposed	2 / 353 (0.57%)	2 / 353 (0.57%)	0 / 353 (0.00%)
occurrences (all)	3	2	0
Rash papular			
subjects affected / exposed	1 / 353 (0.28%)	2 / 353 (0.57%)	0 / 353 (0.00%)
occurrences (all)	1	2	0
Alopecia			
subjects affected / exposed	0 / 353 (0.00%)	2 / 353 (0.57%)	0 / 353 (0.00%)
occurrences (all)	0	2	0
Rash			
subjects affected / exposed	2 / 353 (0.57%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	2	0	0
Skin hypopigmentation			
subjects affected / exposed	0 / 353 (0.00%)	2 / 353 (0.57%)	0 / 353 (0.00%)
occurrences (all)	0	2	0
Acne infantile			

subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Dandruff			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Dermatitis			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Rash generalised			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	0	1	0
Urticaria			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	0	1	0
Dermatitis contact			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	1 / 353 (0.28%)
occurrences (all)	0	0	1
Tenderness (Any) Infant Series Dose 1 and Toddler Dose			
Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.			
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[21]</sup>	217 / 347 (62.54%)	207 / 347 (59.65%)	0 / 353 (0.00%)
occurrences (all)	217	207	0
Tenderness (Significant) Infant Series Dose 1 and Toddler Dose			
Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.			
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[22]</sup>	144 / 341 (42.23%)	139 / 343 (40.52%)	0 / 353 (0.00%)
occurrences (all)	144	139	0
Induration (Any) Infant Series Dose 1 and Toddler Dose			
Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.			
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed <sup>[23]</sup>	73 / 339 (21.53%)	77 / 342 (22.51%)	0 / 353 (0.00%)
occurrences (all)	73	77	0
Induration (Mild) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[24]</sup>	65 / 338 (19.23%)	65 / 340 (19.12%)	0 / 353 (0.00%)
occurrences (all)	65	65	0
Induration (Moderate) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[25]</sup>	16 / 331 (4.83%)	19 / 338 (5.62%)	0 / 353 (0.00%)
occurrences (all)	16	19	0
Erythema (Any) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[26]</sup>	42 / 333 (12.61%)	45 / 339 (13.27%)	0 / 353 (0.00%)
occurrences (all)	42	45	0
Erythema (Mild) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[27]</sup>	38 / 333 (11.41%)	40 / 338 (11.83%)	0 / 353 (0.00%)
occurrences (all)	38	40	0
Erythema (Moderate) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[28]</sup>	5 / 330 (1.52%)	6 / 337 (1.78%)	0 / 353 (0.00%)
occurrences (all)	5	6	0
Tenderness (Any) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed <sup>[29]</sup>	126 / 284 (44.37%)	124 / 282 (43.97%)	0 / 353 (0.00%)
occurrences (all)	126	124	0
Tenderness (Significant) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[30]</sup>	74 / 278 (26.62%)	78 / 279 (27.96%)	0 / 353 (0.00%)
occurrences (all)	74	78	0
Induration (Any) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[31]</sup>	58 / 281 (20.64%)	52 / 278 (18.71%)	0 / 353 (0.00%)
occurrences (all)	58	52	0
Induration (Mild) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[32]</sup>	47 / 281 (16.73%)	45 / 277 (16.25%)	0 / 353 (0.00%)
occurrences (all)	47	45	0
Induration (Moderate) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[33]</sup>	14 / 273 (5.13%)	11 / 272 (4.04%)	0 / 353 (0.00%)
occurrences (all)	14	11	0
Erythema (Any) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[34]</sup>	38 / 275 (13.82%)	50 / 280 (17.86%)	0 / 353 (0.00%)
occurrences (all)	38	50	0
Erythema (Mild) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed <sup>[35]</sup>	36 / 275 (13.09%)	44 / 279 (15.77%)	0 / 353 (0.00%)
occurrences (all)	36	44	0
Erythema (Moderate) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[36]</sup>	4 / 273 (1.47%)	8 / 273 (2.93%)	0 / 353 (0.00%)
occurrences (all)	4	8	0
Tenderness (Any) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[37]</sup>	76 / 204 (37.25%)	76 / 200 (38.00%)	0 / 353 (0.00%)
occurrences (all)	76	76	0
Tenderness (Significant) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[38]</sup>	48 / 199 (24.12%)	46 / 196 (23.47%)	0 / 353 (0.00%)
occurrences (all)	48	46	0
Induration (Any) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[39]</sup>	34 / 198 (17.17%)	27 / 195 (13.85%)	0 / 353 (0.00%)
occurrences (all)	34	27	0
Induration (Mild) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[40]</sup>	31 / 196 (15.82%)	23 / 195 (11.79%)	0 / 353 (0.00%)
occurrences (all)	31	23	0
Induration (Moderate) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			

alternative assessment type: Systematic subjects affected / exposed <sup>[41]</sup> occurrences (all)	5 / 193 (2.59%) 5	7 / 193 (3.63%) 7	0 / 353 (0.00%) 0
Erythema (Any) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[42]</sup> occurrences (all)	20 / 192 (10.42%) 20	19 / 195 (9.74%) 19	0 / 353 (0.00%) 0
Erythema (Mild) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[43]</sup> occurrences (all)	20 / 192 (10.42%) 20	18 / 195 (9.23%) 18	0 / 353 (0.00%) 0
Erythema (Moderate) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[44]</sup> occurrences (all)	0 / 191 (0.00%) 0	1 / 193 (0.52%) 1	0 / 353 (0.00%) 0
Musculoskeletal and connective tissue disorders Rickets subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
Infections and infestations Rhinitis subjects affected / exposed occurrences (all)	47 / 353 (13.31%) 57	37 / 353 (10.48%) 50	0 / 353 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	39 / 353 (11.05%) 56	45 / 353 (12.75%) 53	2 / 353 (0.57%) 2
Nasopharyngitis subjects affected / exposed occurrences (all)	11 / 353 (3.12%) 14	17 / 353 (4.82%) 20	0 / 353 (0.00%) 0
Gastroenteritis			



subjects affected / exposed	8 / 353 (2.27%)	5 / 353 (1.42%)	0 / 353 (0.00%)
occurrences (all)	10	5	0
Lower respiratory tract infection			
subjects affected / exposed	5 / 353 (1.42%)	2 / 353 (0.57%)	1 / 353 (0.28%)
occurrences (all)	5	2	1
Bronchiolitis			
subjects affected / exposed	4 / 353 (1.13%)	2 / 353 (0.57%)	0 / 353 (0.00%)
occurrences (all)	4	2	0
Respiratory tract infection			
subjects affected / exposed	2 / 353 (0.57%)	3 / 353 (0.85%)	0 / 353 (0.00%)
occurrences (all)	2	3	0
Bronchopneumonia			
subjects affected / exposed	2 / 353 (0.57%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	2	1	0
Otitis media			
subjects affected / exposed	2 / 353 (0.57%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	2	1	0
Viral infection			
subjects affected / exposed	2 / 353 (0.57%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	2	1	0
Acarodermatitis			
subjects affected / exposed	0 / 353 (0.00%)	2 / 353 (0.57%)	0 / 353 (0.00%)
occurrences (all)	0	2	0
Omphalitis			
subjects affected / exposed	1 / 353 (0.28%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	1	1	0
Viral diarrhoea			
subjects affected / exposed	2 / 353 (0.57%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	2	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 353 (0.28%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	1	1	0
Abscess neck			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	0	1	0
Body tinea			

subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	1 / 353 (0.28%)
occurrences (all)	0	1	1
Bronchitis			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	2	0	0
Fungal infection			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	0	1	0
Impetigo			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Otitis externa			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	0	1	0
Rash pustular			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection viral			
subjects affected / exposed	1 / 353 (0.28%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	1	0	0
Viral rash			
subjects affected / exposed	0 / 353 (0.00%)	1 / 353 (0.28%)	0 / 353 (0.00%)
occurrences (all)	0	1	0
Tuberculosis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	0	0	0
Furuncle			
subjects affected / exposed	0 / 353 (0.00%)	0 / 353 (0.00%)	0 / 353 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			

Decreased appetite subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0	0 / 353 (0.00%) 0
--	----------------------	----------------------	----------------------

<b>Non-serious adverse events</b>	After the Infant Series 7vPnC	Toddler Dose 13vPnC	Toddler Dose 7vPnC
Total subjects affected by non-serious adverse events subjects affected / exposed occurrences (all)	9 / 353 (2.55%) 0	98 / 198 (49.49%) 1	98 / 200 (49.00%) 1
Vascular disorders Pallor subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 198 (0.51%) 1	1 / 200 (0.50%) 1
Pregnancy, puerperium and perinatal conditions Umbilical granuloma subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
General disorders and administration site conditions Injection site pain subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Injection site swelling subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	2 / 198 (1.01%) 2	6 / 200 (3.00%) 6
Injection site erythema subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Injection site nodule subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Irritability subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Tenderness			

subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Fever $\geq 38^{\circ}\text{C}$ but $\leq 39^{\circ}\text{C}$ Infant Series Dose 1 and Toddler Dose  alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[1]</sup> occurrences (all)	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	0 / 353 (0.00%) 0	9 / 161 (5.59%) 9	10 / 154 (6.49%) 10
Fever $> 39^{\circ}\text{C}$ but $\leq 40^{\circ}\text{C}$ Infant Series Dose 1 and Toddler Dose  alternative dictionary used: Systemic events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[2]</sup> occurrences (all)	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	0 / 353 (0.00%) 0	1 / 160 (0.63%) 1	0 / 152 (0.00%) 0
Fever $> 40^{\circ}\text{C}$ Dose Infant Series Dose 1 and Toddler Dose  alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[3]</sup> occurrences (all)	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	0 / 353 (0.00%) 0	0 / 160 (0.00%) 0	0 / 152 (0.00%) 0
Decreased appetite Infant Series Dose 1 and Toddler Dose  alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[4]</sup> occurrences (all)	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	0 / 353 (0.00%) 0	50 / 174 (28.74%) 50	44 / 179 (24.58%) 44
Irritability Infant Series Dose 1 and Toddler Dose  alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[5]</sup> occurrences (all)	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
	0 / 353 (0.00%) 0	67 / 174 (38.51%) 67	64 / 183 (34.97%) 64
Increased sleep Infant Series Dose 1 and Toddler Dose  alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		

subjects affected / exposed <sup>[6]</sup>	0 / 353 (0.00%)	21 / 171 (12.28%)	16 / 170 (9.41%)
occurrences (all)	0	21	16
Decreased sleep Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[7]</sup>	0 / 353 (0.00%)	39 / 172 (22.67%)	48 / 178 (26.97%)
occurrences (all)	0	39	48
Fever ≥38°C but ≤39°C Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[8]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Fever >39°C but ≤40°C Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[9]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Decreased appetite Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[10]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Fever >40°C Dose Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[11]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Irritability Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type:			

Systematic			
subjects affected / exposed <sup>[12]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Increased sleep Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[13]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Decreased sleep Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[14]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Fever ≥38°C but ≤39°C Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[15]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Fever >40°C Dose Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[16]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Decreased appetite Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[17]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Irritability Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0			

alternative assessment type: Systematic subjects affected / exposed <sup>[18]</sup> occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Increased sleep Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[19]</sup> occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Decreased sleep Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for SE is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed <sup>[20]</sup> occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Immune system disorders Allergy to arthropod bite subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 198 (0.51%) 1	0 / 200 (0.00%) 0
Reproductive system and breast disorders Penile adhesion subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	2 / 353 (0.57%) 2	5 / 198 (2.53%) 6	6 / 200 (3.00%) 6
Upper airway obstruction subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Productive cough			

subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Wheezing subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Bronchial hyperreactivity subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Asthma subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 198 (0.51%) 1	0 / 200 (0.00%) 0
Injury, poisoning and procedural complications Head injury subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Congenital, familial and genetic disorders Macrocephaly subjects affected / exposed occurrences (all)	1 / 353 (0.28%) 1	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Phimosi subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 198 (0.51%) 1	0 / 200 (0.00%) 0
Cardiac disorders Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Nervous system disorders			



Crying subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Convulsion subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Somnolence subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	1 / 198 (0.51%) 1	2 / 200 (1.00%) 3
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Otorrhoea subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Eye disorders Eye discharge subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Lacrimation increased subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 353 (0.00%) 0	0 / 198 (0.00%) 0	0 / 200 (0.00%) 0
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	0 / 353 (0.00%)	1 / 198 (0.51%)	3 / 200 (1.50%)
occurrences (all)	0	1	3
Vomiting			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Infantile colic			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Abdominal discomfort			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Perianal erythema			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Rash			

subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Skin hypopigmentation			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Acne infantile			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Dandruff			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Rash generalised			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Tenderness (Any) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[21]</sup>	0 / 353 (0.00%)	52 / 174 (29.89%)	54 / 176 (30.68%)
occurrences (all)	0	52	54
Tenderness (Significant) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed <sup>[22]</sup>	0 / 353 (0.00%)	27 / 171 (15.79%)	29 / 170 (17.06%)
occurrences (all)	0	27	29
Induration (Any) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[23]</sup>	0 / 353 (0.00%)	34 / 173 (19.65%)	31 / 176 (17.61%)
occurrences (all)	0	34	31
Induration (Mild) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[24]</sup>	0 / 353 (0.00%)	27 / 170 (15.88%)	26 / 175 (14.86%)
occurrences (all)	0	27	26
Induration (Moderate) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[25]</sup>	0 / 353 (0.00%)	9 / 170 (5.29%)	13 / 171 (7.60%)
occurrences (all)	0	9	13
Erythema (Any) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[26]</sup>	0 / 353 (0.00%)	26 / 174 (14.94%)	25 / 176 (14.20%)
occurrences (all)	0	26	25
Erythema (Mild) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[27]</sup>	0 / 353 (0.00%)	21 / 172 (12.21%)	19 / 175 (10.86%)
occurrences (all)	0	21	19
Erythema (Moderate) Infant Series Dose 1 and Toddler Dose	Additional description: Dose 1 and Toddler Dose: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed <sup>[28]</sup>	0 / 353 (0.00%)	6 / 169 (3.55%)	7 / 170 (4.12%)
occurrences (all)	0	6	7
Tenderness (Any) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[29]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Tenderness (Significant) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[30]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Induration (Any) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[31]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Induration (Mild) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[32]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Induration (Moderate) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[33]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Erythema (Any) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed <sup>[34]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Erythema (Mild) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[35]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Erythema (Moderate) Infant Series Dose 2	Additional description: Dose 2: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[36]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Tenderness (Any) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[37]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Tenderness (Significant) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[38]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Induration (Any) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed <sup>[39]</sup>	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Induration (Mild) Infant Series Dose 3	Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaries cannot be used to distinguish one occurrence from another within a subject/vaccination.		
alternative dictionary used: Local Reactions 0.0			

<p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[40]</sup></p> <p>occurrences (all)</p>	<p>0 / 353 (0.00%)</p> <p>0</p>	<p>0 / 198 (0.00%)</p> <p>0</p>	<p>0 / 200 (0.00%)</p> <p>0</p>
<p>Induration (Moderate) Infant Series Dose 3</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[41]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
<p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[41]</sup></p> <p>occurrences (all)</p>	<p>0 / 353 (0.00%)</p> <p>0</p>	<p>0 / 198 (0.00%)</p> <p>0</p>	<p>0 / 200 (0.00%)</p> <p>0</p>
<p>Erythema (Any) Infant Series Dose 3</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[42]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
<p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[42]</sup></p> <p>occurrences (all)</p>	<p>0 / 353 (0.00%)</p> <p>0</p>	<p>0 / 198 (0.00%)</p> <p>0</p>	<p>0 / 200 (0.00%)</p> <p>0</p>
<p>Erythema (Mild) Infant Series Dose 3</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[43]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
<p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[43]</sup></p> <p>occurrences (all)</p>	<p>0 / 353 (0.00%)</p> <p>0</p>	<p>0 / 198 (0.00%)</p> <p>0</p>	<p>0 / 200 (0.00%)</p> <p>0</p>
<p>Erythema (Moderate) Infant Series Dose 3</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[44]</sup></p> <p>occurrences (all)</p>	<p>Additional description: Dose 3: Subjects affected and occurrences for LR is same as data collected through ediaris cannot be used to distinguish one occurrence from another within a subject/vaccination.</p>		
<p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed<sup>[44]</sup></p> <p>occurrences (all)</p>	<p>0 / 353 (0.00%)</p> <p>0</p>	<p>0 / 198 (0.00%)</p> <p>0</p>	<p>0 / 200 (0.00%)</p> <p>0</p>
<p>Musculoskeletal and connective tissue disorders</p> <p>Rickets</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 353 (0.28%)</p> <p>1</p>	<p>0 / 198 (0.00%)</p> <p>0</p>	<p>0 / 200 (0.00%)</p> <p>0</p>
<p>Infections and infestations</p> <p>Rhinitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Upper respiratory tract infection</p>	<p>3 / 353 (0.85%)</p> <p>3</p>	<p>1 / 198 (0.51%)</p> <p>1</p>	<p>4 / 200 (2.00%)</p> <p>4</p>

subjects affected / exposed	2 / 353 (0.57%)	11 / 198 (5.56%)	6 / 200 (3.00%)
occurrences (all)	2	13	6
Nasopharyngitis			
subjects affected / exposed	1 / 353 (0.28%)	1 / 198 (0.51%)	2 / 200 (1.00%)
occurrences (all)	1	1	2
Gastroenteritis			
subjects affected / exposed	0 / 353 (0.00%)	2 / 198 (1.01%)	3 / 200 (1.50%)
occurrences (all)	0	2	3
Lower respiratory tract infection			
subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Bronchiolitis			
subjects affected / exposed	0 / 353 (0.00%)	1 / 198 (0.51%)	0 / 200 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Bronchopneumonia			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Acarodermatitis			
subjects affected / exposed	0 / 353 (0.00%)	1 / 198 (0.51%)	0 / 200 (0.00%)
occurrences (all)	0	1	0
Omphalitis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Viral diarrhoea			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			



subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Abscess neck			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Body tinea			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Fungal infection			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Impetigo			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Otitis externa			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 353 (0.00%)	1 / 198 (0.51%)	0 / 200 (0.00%)
occurrences (all)	0	1	0
Viral rash			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	0	0	0
Tuberculosis			

subjects affected / exposed	1 / 353 (0.28%)	0 / 198 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Furuncle			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 353 (0.00%)	0 / 198 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.



Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 August 2007	1- Volume of blood samples reduced from 5mL to 3mL based on the actual weight of babies enrolled in the study as some infants were too small for a 5-mL blood draw at 18 weeks of age as specified in the study protocol. 2- An additional inclusion criterion of subject weight of 3.5 kg or greater at the time of enrollment was added.
13 February 2008	1- A cohort 2 was added to the study because the original subjects would not be fully representative of a 6-, 10-, and 14-week infant series schedule owing to the clinical hold. 2- Analysis endpoint for the pertussis responses was modified from the specific cutoff of 5 EU/mL to a comparison based on the level of serum IgG attained by 95% of subjects in the 7vPnC group. 3- Coprimary whole-cell pertussis antigens endpoint was changed to a primary endpoint. 4- A second interim analysis for the cohort 2 infant series was allowed.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
10 October 2007	This study was placed temporarily on clinical hold to allow review of safety data. It was suspended based on the review of 4 serious adverse events (SAEs) reported as serious, unexpected, and possibly related by investigators from studies of 13vPnC or 7vPnC conducted outside of India. All 4 of the SAEs considered to be possibly related to vaccine by the investigator and reviewed by the Drug Controller General of India DCG(I) occurred in subjects who received the comparator 7vPnC, that is (ie), Prevenar.	01 December 2007
07 November 2008	The study was put temporarily on hold at all sites due to the death of a subject. This occurred 1 week after administration of the 14-week vaccination. The SAE was reported as possibly related to test article, and a report was generated. The investigator subsequently changed the causality assessment to "not related" to vaccination.	01 April 2009

Notes:

### Limitations and caveats

None reported